On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the August 2025 CRG meeting. Actions in this consultation include:
- Ivermectin 3mg tablets for scabies – green, second line
- Sodium fusidate 250mg tablets and 250mg/5ml oral suspension – remove from formulary (discontinued)
- Hypurin vials – remove from formulary (discontinued)
- Humulin I, Humulin M3, Hunulin S, Humalog Mix25 vials – remove from formulary (discontinued)
- NICE TA1077: Nemolizumab for atopic dermatitis – red
- NICE TA1088: Mirikizumab for Crohn’s disease – red
- NICE TA1085: Vanzacaftor-tezacaftor-deutivacaftor for cystic fibrosis – red
All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.
This consultation will run for six weeks and closes at 5pm on Monday 29th September 2025. To take part, visit the consultations page.